Evidence map›Paper›PMID 39904730›Full record

SynthesisEuropean psychiatry : the journal of the Association of European Psychiatrists2025

Respiratory disease in people with major depressive disorder: A systematic review and Meta-analysis.

Ana Jiménez-Peinado, David Laguna-Muñoz, María José Jaén-Moreno, Cristina Camacho-Rodríguez, Gloria Isabel Del Pozo, Eduard Vieta, Javier Caballero-Villarraso, Fernando Rico-Villademoros, Fernando Sarramea

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in European psychiatry : the journal of the Association of European Psychiatrists, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ana Jiménez-PeinadoMaimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain.ORCID 0009-0001-0401-8801
David Laguna-MuñozMaimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain.ORCID 0009-0005-1816-3953
María José Jaén-MorenoMaimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain.ORCID 0000-0003-0905-901X
Cristina Camacho-RodríguezMaimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain.ORCID 0009-0009-5542-8374
Gloria Isabel Del PozoMaimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain.
Eduard VietaDepartment of Medicine, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Catalonia, Spain.ORCID 0000-0002-0548-0053
Javier Caballero-VillarrasoMaimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain.ORCID 0000-0003-0571-5147
Fernando Rico-VillademorosInstituto de Neurociencias, Universidad de Granada, Granada, Spain.ORCID 0000-0002-1154-5095
Fernando SarrameaMaimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiving with major depressive disorder (MDD) reduces life expectancy, with respiratory disease being a significant threat. However, evidence on respiratory disease in this population has not yet been meta-analyzed.

methodsThis meta-analysis examines respiratory disease prevalence and odds ratio (OR) in patients with MDD and treatment resistant depression (TRD). A systematic literature search was conducted, with a snowball search of reference and citation lists. Inclusion criteria covered studies in MDD and TRD patients with confirmed diagnoses of respiratory diseases (asthma, chronic obstructive pulmonary disease [COPD], pneumonia, lung cancer, and tuberculosis), comparing with a control group when possible.

resultsFrom 4,138 retrieved articles, 15 (including 476,927 individuals with MDD, 50,680 with TRD, and 1,108,979 control group) met the inclusion criteria. In MDD patients, COPD prevalence was 9.0% (95% CI: 3.8-19.6%), asthma 8.6% (95% CI: 5.7-12.8%), and pneumonia 2.5% (95% CI: 2.2-2.9%). In TRD patients, COPD prevalence was 9.9% (95% CI: 4.2-21.9%) and asthma 10.9% (95% CI: 10.7-11.2%), but meta-analysis limited to those diseases showed no significant relative risk differences. Compared to the general population, individuals with MDD had significantly higher rates of COPD (OR 1.79, 95% CI: 1.49-2.16), even higher in younger populations (1.85 [95% CI: 1.74-1.97]) and more prevalent in women.

conclusionsThis first meta-analysis on this topic shows that MDD is associated with an increased risk of respiratory illness compared to the general population. The prevalence of asthma doubles the mean described in the general population worldwide, and in COPD, women and younger people are at particular risk. Prevention policies are urgently needed.

Indexed as

AsthmaDepressive Disorder, Treatment-ResistantMajor Depressive DisorderPulmonary Disease, Chronic ObstructiveComorbidityFemaleHumansPrevalenceasthmachronic obstructive pulmonary diseasemajor depressive disorderprevalencerespiratory conditionstreatment resistant depression

Identifiers

PMID39904730
PMCPMC11883783

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.